Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Great. Good afternoon. Thank you, everyone, for joining us. We're really pleased to have Alnylam with us. And from Alnylam, we have Jeff Poulton, CFO. So Jeff, with that, I'll turn it over to you for any opening comments and jump in.
Thanks, Salveen. It's great to be here. This is -- when this conference comes up and it's in person, I always raise my hand first to come to this one. So thanks for having us. Great to be here. I did want to share one piece of good news that literally, I got about 5 minutes before I was supposed to come on stage that we got word from the FDA this afternoon that we've got approval for vutrisiran and the hereditary ATTR PN population. So this marks the fifth RNAi therapeutic that will be on the market. So we're very excited about that. We should have a press release out momentarily on this, and then we'll have an investor call tomorrow morning. So I just wanted to get the word out on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
